Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0079731 (
B-cell lymphoma
)
16,671
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mammalian orosomucoid-like gene family (
ORMDL
), containing
ORMDL1
,
ORMDL2
, and
ORMDL3
, is the important regulator of sphingolipid metabolism, which is relevant to cell growth, proliferation, migration, and invasion. Since the role of
ORMDL1
in cancers remained unclear, the main purpose of our study was to explore the expression patterns and prognostic values of
ORMDL1
in different tumors, especially in cholangiocarcinoma (CHOL), lymphoid neoplasm diffuse large
B cell lymphoma
(DLBCL), acute myeloid leukemia (LAML), and thymoma (THYM). Bioinformatics tools including GEPIA, CCLE, LinkedOmics, cBioPortal, and TIMER databases were used. As a result, the expression levels of
ORMDL1
in tumor tissues and normal tissues varied in different cancers, especially significantly upregulated in CHOL, DLBCL, LAML, and THYM. Moreover,
ORMDL1
mRNA was also highly expressed in cell lines of DLBCL and LAML. Further studies showed that
ORMDL1
overexpression was associated with poor prognosis in DLBCL, but not significant in CHOL, LAML, and THYM. Consistently, there were genetic alterations of
ORMDL1
in DLBCL, and patients with genetic alterations indicated worse survival. Coexpressed genes and related biological events with
ORMDL1
in DLBCL were found via LinkedOmics, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The relationship between
ORMDL1
and cancer immune cells was investigated, and
ORMDL1
expression was positively correlated with infiltrating levels of B cells. In conclusion,
ORMDL
1 is suggested to be a tumorigenic factor and considered as the potential therapeutic target and prognostic biomarker in DLBCL.
...
PMID:Expression Patterns and Prognostic Values of ORMDL1 in Different Cancers. 3314 51